Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • treat

    Tag: treat

    You Searched For "treat"
    Pfizer gets USFDA approval for Fragmin to treat blood clot in pediatric patients

    Pfizer gets USFDA approval for Fragmin to treat blood clot in pediatric patients

    Farhat Nasim19 May 2019 4:15 AM GMT
    The efficacy of Fragmin in children was based on a single trial with 38 pediatric patients with symptomatic deep vein thrombosis and/or pulmonary embol...
    Zydus Cadila gets USFDA nod for Chlorthalidone tablets to treat high BP

    Zydus Cadila gets USFDA nod for Chlorthalidone tablets to treat high BP

    Farhat Nasim13 May 2019 5:01 AM GMT
    Zydus Cadila said Chlorthalidone tablets will be manufactured at the group's formulations manufacturing facility at SEZ, Ahmedabad.New Delhi: Drug...
    Alembic Pharma gets USFDA nod for Olopatadine Hydrochloride ophthalmic solution

    Alembic Pharma gets USFDA nod for Olopatadine Hydrochloride ophthalmic solution

    Farhat Nasim17 Feb 2019 4:00 AM GMT
    The company has received approval from the US Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) Olopatadine Hydrochl...
    Pfizer says USFDA accepts regulatory submissions for review of tafamidis

    Pfizer says USFDA accepts regulatory submissions for review of tafamidis

    Medical Dialogues Bureau16 Jan 2019 4:05 AM GMT
    Pfizer has submitted two NDAs based on two forms of tafamidis: meglumine salt and free acid. Tafamidis is the only product to complete a Phase 3 trial ...

    Popular Stories

    • Email: info@medicaldialogues.in
    • Phone: 011 - 4372 0751

    Website Last Updated On : 27 May 2022 6:45 AM GMT
    Company
    • About Us
    • Contact Us
    • Our Team
    • Reach our Editor
    • Feedback
    • Submit Article
    Ads & Legal
    • Advertise
    • Advertise Policy
    • Terms and Conditions
    • Privacy Policy
    • Editorial Policy
    • Comments Policy
    • Disclamier

    This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
    verify here.

    Search only trustworthy HONcode health websites:

    Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

    Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2020 Minerva Medical Treatment Pvt Ltd

    © 2020 - Medical Dialogues. All Rights Reserved.
    Powered By: Hocalwire
    We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok
    X
    X